The aim of this post market study is to assess the impact of sleep-disordered breathing on the well-being of patients according to the treatment chosen, i.e. with or without implantation of the remedē® system to treat sleep-disordered breathing.
The sponsor of this study, LivaNova, has a partnership with Respicardia, Inc who has developed a battery-powered implantable device that treats central sleep apnea. The device is used with a lead that delivers the stimulation therapy which causes the patient to breathe with a regular rhythm and an optional lead that senses breathing. This combination is called the remedē® system. The aim of this study is 1. to collect data in order to get a better understanding of the characteristics and/or symptoms related to central sleep apnea 2. to collect safety information of all patients diagnosed with central sleep apnea 3. to obtain additional short and lang term information on the safety and performance of the remedē® system, including an evaluation if there's an impact on the quality of life of patients treated with the the remedē® system in daily practice. The information obtained from this study may provide better insight on the symptoms related to central sleep apnea, risk factors related to central sleep apnea therapy and use of the remedē® system which may help to treat other patients with potential sleep disordered breathing more appropriately. Approximately 300 patients (to be) implanted with the remedē® system will participate in this study at approximately 40 sites in Europe. For this purpose the investigators aim to screen approximately 1500 patients with sleep-disordered breathing. Also patients diagnosed with central sleep apnea, but not receiving the device will be followed through phone calls for 2 years.
Study Type
OBSERVATIONAL
Enrollment
31
Herz- und Diabeteszentrum Bad Oeynhausen
Bad Oeynhausen, Germany
Klinikum Bielefeld Mitte
Bielefeld, Germany
Alice Hospital
Darmstadt, Germany
Albertinen Krankenhaus
Hamburg, Germany
Incidence of All Cause Mortality, SAEs, Stimulation Complaints, Device and/or Cardiovascular Related Events From Implant up to 5 Years.
Collect short and long term clinical data on safety of the remede system implanted in daily practice. This outcome measure was intended to be collected up to 5 years, but at time of early study termination the data were only monitored until 24 months for 1 patient.
Time frame: From implant up to 5 years (collected until 24 month FU)
Change in Apnea-hypopnea Index as Assessed by Polygraphy Compared to Baseline
Evaluate changes in sleep study results at 12 months compared to baseline
Time frame: 12 months post-implant
Impact on Quality of Life Compared to Baseline
Evaluate impact on Quality of Life by using a general questionnaire, a sleep-specific questionnaire and a questionnaire specific for heart failure patients
Time frame: Up to 5 years post-implant
Change in Reverse Remodelling Response as Assessed by Echo Compared to Baseline
Evaluate reverse remodeling response in patients with reduced ejection fraction at baseline
Time frame: 12 months post implant
Incidence of All Cause Mortality and Hospitalizations up to 2 Years After Diagnosis of Central Sleep Apnea
Collect site reported safety data on all patients diagnosed with central sleep apnea and not treated with the remede system
Time frame: Up to 2 years (collected until 6M FU)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Universitaetsklinikum Schleswig Holstein
Kiel, Germany
Klinikum Lünen - St Marien Hospital
Lünen, Germany
St. Vincenz-Krankenhaus
Paderborn, Germany
Hospital Infanta Cristina
Badajoz, Spain
Hospital Universitario de Burgos
Burgos, Spain
Hospital de Monteprincipe
Madrid, Spain